Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD : A multicenter phase 2 study
Journal of Internal Medicine · 2024
DOI: 10.1111/joim.13738 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Sijian Yu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Sulfonamides. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University.
Abstract (Originalsprache)
Background
Patients with relapsed or refractory acute myeloid leukemia (R/R AML) and FLT3 ‐internal tandem duplication ( FLT3‐ITD ) respond infrequently to salvage chemotherapy.
Objective
To investigate the efficacy of sorafenib plus triplet therapy with venetoclax, azacitidine, and homoharringtonine (VAH) as a salvage therapy in this population.
Methods
This multicenter, single‐arm, phase 2 study was conducted at 12 hospitals across China. Eligible patients had R/R AML with FLT3‐ITD (aged 18–65 years) who were treated with VAH. The primary endpoint was composite complete remission (CRc) after two cycles. Secondary outcomes included the overall response rate (ORR), safety, and survival.
Results
Between July 9, 2020, and March 19, 2022, 58 patients were assessed for eligibility, 51 of whom were enrolled. The median patient age was 47 years (interquartile range [IQR] 31–57). CRc was 76.5% with ORR of 82.4%. At a median follow‐up of 17.7 months (IQR, 8.7–24.7), the median duration of CRc was not reached (NR), overall survival was 18.1 months (95% confidence interval [CI], 11.8‐NR) and event‐free survival was 11.4 months (95% CI, 5.6‐NR). Grade 3 or 4 adverse events occurring in ≥10% of patients included neutropenia in 47 (92.2%), thrombocytopenia in 41 (80.4%), anemia in 35 (68.6%), febrile neutropenia in 29 (56.9%), pneumonia in 13 (25.5%), and sepsis in 6 (11.8%) patients. Treatment‐related death occurred in two (3.9%) patients.
Conclusions
The sorafenib plus VAH regimen was well tolerated and highly active against R/R AML with FLT3‐ITD . This regimen may be a suitable therapeutic option for this population, but larger population trials are needed to be explored.
Trial registration
Clinical Trials Registry: NCT04424147
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
- Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
- Peking Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
- Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
ORCID-Profile: Qifa Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University
- Clinical Research Program of Nanfang Hospital, Southern Medical University
Zitieren
APA
Yu, S., Zhang, Y., Yu, G., Wang, Y., Shao, R., Du, X., Xu, N., Lin, D., Zhao, W., Zhang, X., Xiao, J., Sun, Z., Deng, L., Liang, X., Zhang, H., Guo, Z., Dai, M., Shi, P., Huang, F., …, & Jin, H. (2024). Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD : A multicenter phase 2 study. Journal of Internal Medicine. https://doi.org/10.1111/joim.13738
Vancouver
Yu S, Zhang Y, Yu G, Wang Y, Shao R, Du X, et al. Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD : A multicenter phase 2 study. Journal of Internal Medicine. 2024. doi:10.1111/joim.13738
BibTeX
@article{Yu2024,
author = {Yu, Sijian and Zhang, Yu and Yu, Guopan and Wang, Yu and Shao, Ruoyang and Du, Xin and Xu, Na and Lin, Dongjun and Zhao, Weihua and Zhang, Xiong and Xiao, Jie and Sun, Zhiqiang and Deng, Lan and Liang, Xinquan and Zhang, Hongyu and Guo, Ziwen and Dai, Min and Shi, Pengcheng and Huang, Fen and Fan, Zhiping and Liu, Qiong and Lin, Ren and Jiang, Xuejie and Xuan, Li and Liu, Qifa and Jin, Hua},
title = {Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD : A multicenter phase 2 study},
journal = {Journal of Internal Medicine},
year = {2024},
doi = {10.1111/joim.13738}
}
EUVIMED